posted
Not directly related to DNAP. I wish it said they used DNA Witness by DNAP, but...
Suspects Get Snared by a Relative's DNA
By Richard Willing, USA TODAY
Lab technicians in North Carolina didn't have Willard Brown's DNA on file, but they had his brother's. And these days, that can be good enough to solve a murder.
· How DNA Fragments Are Matched
Searching for the man who raped and killed a Winston-Salem newspaper editor, the technicians in 2003 compared DNA left at the crime scene with the genetic profiles in the state's database of convicted felons. The crime scene DNA didn't match any of the 40,000 felons on file, but it did offer a clue: The unknown man's profile was remarkably similar to that of one convict, Anthony Dennard Brown.
The technicians concluded that Brown and the man they were seeking probably had inherited their DNA — a cellular acid that carries a person's unique genetic code — from the same parents.
Detectives took it from there. They found Brown's brother, Willard, scooped up the butts of cigarettes he had smoked and discarded, and got a sample of his DNA from the saliva. It matched the sample from the crime scene perfectly.
Last December, Willard Brown pleaded guilty to raping and killing Deborah Sykes in 1984 and was sentenced to life in prison plus 10 years. The DNA testing exonerated Darryl Hunt, who had spent 18 years in prison for the crime and had persuaded a court to order the testing.
It sounds like a script from the CSI crime dramas. But the Brown case reflects real-life advances in crime-solving: DNA science, known for its ability to pinpoint suspects' identities with virtual certainty, now is being used to help in*****gators simply get close to their targets.
In*****gators in the USA and the United Kingdom have begun to solve not just crimes committed by convicts whose DNA profiles are in government databases, but also those committed by relatives such as Willard Brown, whose profiles were not on file. Siblings, parents, and even uncles and cousins increasingly are being in*****gated for crimes because their genetic fingerprints closely resemble the DNA of a known criminal. ....
DNAPrint Selects Proteos to Manufacture PT-401 for Pre-Clinical Evaluation E-mail or Print this story
14 June 2005, 09:44am ET
SARASOTA, Fla., June 14 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (BB:DNAP) (the "Company") today announced that it has selected Proteos, Inc. to manufacture the first batch of its new therapeutic candidate PT-401 (Super EPO dimer) for pre-clinical testing.
"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chairman and Chief Medical Officer Hector Gomez, M.D., Ph.D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos' staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."
DNAPrint announced in April that it has acquired an exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) to develop a new, more potent and longer acting form of the anemia drug erythropoietin. DNAPrint is working on the project with Dr. Arthur J. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess. The PT-401 to be manufactured by Proteos will be used to generate pre-clinical data required for an Investigational New Drug (IND) application as required by the U.S. Food and Drug Administration.
"We are now beginning the clinical development process and today's announcement is a major step for DNAPrint toward compiling the data for its first IND application," stated President and Chief Executive Officer Richard Gabriel. "Dr. Sytkowski, who has worked his entire career on Erythropoietin and similar molecules, and Dr. Gomez selected Proteos for its technical skills and background and will monitor the data collection very closely."
DNAPrint also announced that it has agreed to a six-month contract with Dr. Sytkowski to provide continued support for the completion of the PT-401 clinical research program. "Dr. Sytkowski holds eight patents covering this technology and is the author of a book on the subject, 'Erythropoietin, Blood, Brain and Beyond.' He brings a knowledge base to the development of our licensed product, and his agreement is structured to give him appropriate incentives to help move the product through clinical development," Dr. Gomez stated.
About Proteos
Mentioned Last Change DNAP 0.0143 (Unchanged) Proteos, Inc. ( http://www.proteos.net ) is a provider of high quality proteins and peptides for enabling and facilitating drug discovery. The Proteos Process includes target identification, expression using various cell lines, purification and production of proteins. Unique protein services include Expression in baculovirus, mammalian cells, and E coli, Refolding of proteins from inclusion bodies, Purification, and Assay Development. Peptide services include Design and Modification, and Antigen Design, Production and Purification. Proteos, based in Kalamazoo, Mich., was founded by eight scientists following the August 2002 acquisition of Pharmacia by Pfizer, Inc.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.
posted
Tough road for DNAP, BUT --- news just out pretty much proves this stock is worth at least .02 pps.. Look at the option:
Press Release Source: DNAPrint genomics
DNAPrint genomics Acquires Trace Genetics of San Francisco Tuesday June 21, 10:44 am ET Company's New Base of Operations on West Coast Opens Up New Markets
SARASOTA, Fla., June 21 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that it has acquired Trace Genetics, Inc., of San Francisco, Calif., a provider of products and services for the genealogy, forensics, and molecular diagnostics markets. In the all- stock transaction, Trace shareholders exchanged all of the outstanding shares of Trace for 25,000,000 shares of DNAPrint common stock and options to purchase 5,000,000 additional shares at $0.02 share. "The acquisition enables DNAPrint to establish a base of operations in the San Francisco Bay biotech corridor and broadens our sales and marketing opportunities on the West Coast," stated President and Chief Executive Officer Richard Gabriel. "By centralizing our consumer genomics and law enforcement forensics production work at Trace's state-of-the art custom laboratory in San Francisco, we can concentrate on the acceleration of research and development at our Sarasota headquarters."
Trace ( http://www.tracegenetics.com ) brings two new complementary technologies to DNAPrint's autosomal testing for determining the percentage of a person's ancestry -- y-chromosome testing for tracing ancestry by following the paternal line and mitochondrial (mtDNA) x-chromosome testing for the maternal line. Trace also maintains a Native American DNA databank which, when combined with DNAPrint's, will be one of the largest in North America. In addition, Trace maintains expertise in ancient DNA analysis from mummified and fossilized remains. DNAPrint's proprietary human genome technology is focused on three areas: pharmacogenomics, forensics, and genealogy. All three are based on core technology for targeting single nucleotide polymorphisms (SNPs), which enables the Company to provide novel predictive genetic tests at a significant cost advantage.
Mr. Gabriel noted that Trace's co-founders, Ripan S. Malhi, Ph.D., and Jason Eshelman, Ph.D., will join the staff of DNAPrint genomics. "We are pleased that these two talented scientists are becoming part of the DNAPrint family," Mr. Gabriel stated. "Their expertise will bring an invaluable asset to the Company at a time when we are entering a period of expansion and growth."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.
Forward-Looking Statements
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
IP: Logged |
posted
i've been watching this for a long time.. its got a nice base around .01. i'm in this AM @ .0109 waiting for .02. It might do it soon I hope.
IP: Logged |
posted
Yes, this is a long term stock. I say 2 years for the positive results to show. All their eggs are not in one basket. 1. Forensics with the recent merger and 2.the Pharm, that has an innovative approach. I believe the Bio-Pharm part is what will propel this over $1.00. Just my opinion.
posted
Talk about eggs and DNA. DNAP should look to collaberate with this group to develop fertility drugs
Study: Genetic Profile Helps Pregnancy By EMMA ROSS, AP Medical Writer Tue Jun 21, 8:37 PM ET
COPENHAGEN, Denmark - New research raises the possibility a genetic test may be able to tell young women whether they can afford to delay motherhood while they get their careers on track.
In a study presented Tuesday at a European fertility conference, scientists reported some women who find it easy to conceive after age 45 have a special genetic profile.
Scientists always suspected genes must help those rare "superbreeders" to defy the odds and get pregnant over and over again late in life, but this is the first time it has been proven, said Dr. Hans Evers, former chairman of the European Society of Human Reproduction and Embryology.
Evers, who wasn't involved in the research, said the findings could help women avoid the disappointment of discovering too late that they have become infertile.
"It doesn't work if you tell all the women in the country that they should have their babies in time because they don't feel it pertains to them. But if you can say with a test, 'You personally are at high risk of infertility by 35,' then that would work," said Evers, a professor at Academic University in the Netherlands.
Similarly, he said, test results indicated the right profile could reassure the rare woman who can afford to stretch the timeline a few years.
For most women, fertility gradually declines until age 37, after which it plummets.
In the study, Dr. Neri Laufer from Haddassah University Hospital in Jerusalem, selected from a group of 250 Ashkenazi Jewish women who gave birth after age 45.
Most of the women already had at least six children and rarely suffered miscarriages, which the researchers felt indicated they might have a natural ability to escape the aging of the ovaries.
The researchers looked for differences in the genes between eight women who had conceived after 45 and six women of the same age who had their last baby by age 30.
They found blood samples from all eight women who became pregnant after 45 had a unique genetic profile that did not exist in the other women. Less than 50 genes were responsible for the difference. They all tended to protect against DNA damage and early cell death, which both age the ovaries.
Laufer said he found the same genetic fingerprint in a similar study that he later conducted on Bedouin women. He did not present details of those results.
Pregnancy after 45 is rare because the number and quality of eggs depletes. Girls develop their lifetime supply of eggs by the age of 7 months and throughout their lives the eggs mature and die.
Bill Ledger, professor of reproductive and developmental medicine at the University of Sheffield in England, said it makes sense that the genetic pattern seen in the Israeli study might slow the aging process in the ovaries, thereby making pregnancy possible at later ages.
"What would be happening in these women is that they have more eggs to start with as children so they work through their lifetime supply more slowly. And if these women have a slower rate of loss, they are going to carry on longer," he said.
"A prognostic test would be helpful," if the research findings are shown to apply to women everywhere, Ledger added. "Women want to know this. It's very important information. If you are planning your career, you need to know when to stop and come out and have kids."
Tests that can tell women vaguely how long they have until menopause are already on the horizon. They are imperfect, but adding a genetic test would allow doctors to guess more accurately, Ledger said.
"Right around the corner is hormone testing that gives you some idea of how many eggs you've got left. Do that when you're 30, again when you're 32 and again when you're 34. Plot your individual graph and if it's declining you need to stop doing what you're doing and have your family," he said.
"On the other hand, you may push it a bit longer if your levels are nice and high, but not too long."
posted
DNAPrint CEO Richard Gabriel's Interview With Wall Street Reporter Magazine Available Via Web Cast
SARASOTA, Fla., June 22 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today announced that President and Chief Executive Officer Richard Gabriel is the subject of an interview and web cast with the Wall Street Reporter magazine.
During the interview, which can be accessed free at http://www.******************.com , Mr. Gabriel discussed the future of pharmacogenomics and DNAPrint's recent licensing agreement with the Harvard Medical School's Beth Israel Deaconess Medical Center (BIDC) to clinically develop and commercially implement a new, super-potent form of erythropoietin (EPO), an anemia treatment drug.
"We believe that the recent FDA pronouncements about pharmacogenomics and the importance of understanding genetic ancestry of patients in combination with drug treatments is the wave of the future," Mr. Gabriel stated. "In fact, we see all drugs, or let's say a good majority of those drugs 10, 15, 20 years from now, and this is just my personal opinion, will have what we would call a diagnostic test tied directly to the administration of the drug so everyone knows that it is being personalized medically."
posted
Updated: 07:26 AM EDT DNAPrint genomics Chairman Hector Gomez Tells Annual Meeting That Company Broadens Its Activities
SARASOTA, Fla., June 24 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., told shareholders attending the Annual Meeting yesterday that "the Company's science is the platform technology that will lead to customized medicine, which we believe is the next truly important step in identifying, treating and healing diseases. Great advances in medicine have been made by brilliant doctors and researchers at universities, hospitals and pharmaceutical companies. The mission of DNAPrint genomics and its scientist founders is to maximize these accomplishments by providing doctors a blueprint for the efficacy of various drug treatments, which may vary from person to person with the same disease because of differences in DNA.
"We have put a new face on DNAPrint," Dr. Gomez said. "DNAPrint has successfully leveraged its expertise in DNA technology into the development of pharmacogenomics, in particular, test/drug combinations called 'theranostics.' In addition, we will continue to expand our line of forensic products for the law enforcement market, as well as family ancestry products for individual consumers."
Shareholders attending the Annual Meeting and those voting by proxy approved an amendment to the Company's Articles of Incorporation to effect a stock combination of at least 1-for-10 but no more than 1-for-20 with the exact ratio to be established by the Board of Directors at the time it elects to effect the combination. The purpose for the stock combination is to be able to access up to $40 million in growth capital that has been committed to DNAPrint over the next two years so that the Company can implement its strategic plans for building both its pharmaceutical and forensics divisions. In its pharmaceutical division, DNAPrint will seek to accelerate the development of PT-401, a longer-acting and more potent compound for the anemia drug erythropoietin (EPO), to license new compounds to broaden its pharmaceutical product pipeline, and to accelerate development of its diagnostic testing products. The goal of the forensics division is to create a fully functional and certified forensics laboratory -- either through expansion of the Company's existing facilities or through acquisition.
Dr. Gomez, in an overview of the Company's activities, noted that DNAPrint already has a project under way to develop a new, more potent and long-acting form of the erythropoietin. Working in collaboration with Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC), DNAPrint has begun pre- clinical work on PT-401, a "Super EPO" that would be the Company's first Investigational New Drug (IND) once an application is filed with the U.S. Food and Drug Administration.
Dr. Gomez stated that drugs of the future will be comprised of test/drug combinations for ensuring efficacy with genetically compatible patients. "Theranostics have the potential to reduce adverse patient reactions to new drugs," he said. "Determining beforehand whether a patient will respond positively or negatively to a new drug could save them from undergoing treatments that might be ineffective, debilitating, or even life threatening."
DNAPrint Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., said that scientists and physicians have known for many years that there are inherited genetic differences across global populations and even between and among family members. "These differences are what we all celebrate as our cultural heritage," he said. "Unfortunately some of our genetic heritages often bring prevalence for disease and inabilities to metabolize medicines. Our goal is to develop a genetically based diagnostic assay protocol that enables physicians to prescribe drugs more effectively."
DNAPrint also has two other pharmacogenomic products under development. It is working with the H. Lee Moffitt Cancer Center on the development of OVANOME(TM), a test for predicting an ovarian cancer patient's response to TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse response to cholesterol lowering medicines known as Statins. "Our DNA technology is advancing into new areas while we continue to develop our core genealogy business," Dr. Frudakis said.
DNAPrint also has a growing product line for the forensics market and recently announced that it has begun research with Penn State University on developing 3D biometric applications for the Company's DNAWITNESS(TM) product for law enforcement. It also is completing beta trials on a DNAWITNESS test kit that enables forensics experts to conduct their own tests without sending recovered DNA back to the Company for analysis. In 2004, DNAPrint introduced RETINOME(TM), another valuable tool for forensics investigators which can determine human iris (eye) color from DNA samples.
Dr. Frudakis noted that in 2004 the Company added a new test, EURO-DNA(TM) 1.0, to complement its existing ANCESTRYbyDNA(TM) product targeting consumers who want to learn about their family heritage.
In other action, shareholders re-elected the three-member Board of Directors consisting of Dr. Gomez, Dr. Frudakis and Richard Gabriel, President and Chief Executive Officer.
Shareholders also ratified the selection of Pender, Newkirk and Company as the Company's independent auditors for the fiscal year ending Dec. 31, 2005.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.
posted
It is only a matter of time. The future of medication prescribing?
Government OKs First Racially Targeted Drug Medical Experts Debate Value of Racial Classification By KEVIN FREKING, AP
WASHINGTON (June 24) - Now that the FDA has for the first time approved a drug specifically for blacks, medical experts are sure to debate the implications, with some questioning the validity of medical research that focuses on race.
"There are many, many who claim these use of (racial) categories may not have any biological meaning, only social meaning, and basing medical decisions on them may be problematic,'' said David Magnus, director of the Stanford Medical Center for Biomedical Ethics.
Talk About It
· Chat | Post Messages
For example, Magnus said, researchers could also look at whether a particular drug worked more effectively on Catholics than Protestants. The more categories explored, the more likely one can find data showing that one category of people is helped more than the others when it comes to a particular medicine, he said.
"But the more we know genetically, the more we know these social categories don't correspond to genetic groups,'' Magnus said.
The Food and Drug Administration approved the drug BiDil on Thursday for the treatment of heart failure in black Americans, calling it a step toward "the promise of personalized medicine.''
While that approval may prompt debate, a rejection of BiDil likely would have also raised serious questions.
Data clearly showed that BiDil had a positive effect on a population disproportionately burdened by cardiovascular disease, said Dr. Anne Taylor of the University of Minnesota Medical School and a lead investigator in the research of BiDil.
"African-Americans between the ages of 45 and 64 are 2.5 times more likely to die prematurely from heart failure than their non-black counterparts,'' she said. "FDA approval of BiDil represents an important leap forward in addressing this health disparity.''
FDA officials say that in the case of BiDil researchers did not start out looking for a drug that worked better for a particular racial group. Two earlier trials of the drug on the general population of heart failure patients found no benefit, the FDA said, but they did suggest that BiDil helped the few blacks participating.
Based on those results, NitroMed Inc. of Lexington, Mass., launched a study of 1,050 blacks with severe heart failure. Half of them got standard heart failure drugs and a placebo; the other half got standard drugs plus BiDil. The study showed a 43 percent reduction in deaths and a 39 percent decrease in hospitalizations compared with a placebo, and the study was stopped ahead of schedule last year when doctors saw BiDil clearly was better.
"The information presented to the FDA clearly showed that blacks suffering from heart failure will now have an additional safe and effective option for treating their condition,'' said Dr. Robert Temple, the agency's associate director of medical policy. "In the future, we hope to discover characteristics that identify people of any race who might be helped by BiDil.''
Heart failure occurs when the heart is too weak to pump effectively, causing fluid to back up in the lungs and leaving people weak and short of breath. Half die within five years of diagnosis. Heart failure, or end-stage cardiovascular disease, affects about 5 million Americans, including an estimated 750,000 blacks.
The National Medical Association, which promotes the interests of black physicians and patients in eliminating health disparities, applauded the FDA's decision. The organization also encouraged the scientist involved in testing BiDil to conduct larger clinical trials to see whether it would be helpful to other populations.
"It is our hope that BiDil will be brought to market as quickly as possible to enhance its life saving impact,'' said Dr. Winston Price, president of the National Medical Association. "Any day of delay represents an unacceptable missed opportunity to save lives.''
BiDil is a combination of two older drugs, hydralazine and isosorbide dinitrate, neither of which is approved for heart failure. Some common side effects of the drug are headache and dizziness. The company has yet to announce the price it will charge for the medicine.
posted
The main line in the article I saw was, "But the more we know genetically, the more we know these social categories don't correspond to genetic groups,'' Social grougs don't equal genetic groups. I believe in the future a doctor will take a genetic sample in order to prescribe meds.
posted
DNAPrint genomics Plays Key Role in Investigation of 11-Year-Old Florida Murder Case
SARASOTA, Fla., June 30 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today confirmed that the Company's forensics technology is playing a key role in an effort to solve a baffling 11-year-old murder case, thanks to the efforts of best-selling crime novelist Patricia Cornwall.
A front-page article in the Monday, June 27, edition of The Miami Herald relates how Cornwall introduced the Company's DNA forensics technology to Hollywood, Fla., police, who had hit a stone wall in trying to find a suspect in the murder of an 85-year-old Mildred Weiss, a former legal secretary who was brutally slain in the laundry room of her apartment building in March 1994.
A decade later, author Cornwall alerted Hollywood police to new cutting- edge technology developed by DNAPrint genomics. Police investigators then sent DNA recovered from the crime scene to the Company's laboratory for testing in May 2005. DNAPrint's analysis determined that the killer was black, confirming what police believed to be the case based on a composite sketch drawn from the description of a man seen in the area by local residents before the murder.
The article and a companion story about the Company's DNAWitness(TM) forensic technology also discuss the role that DNAPrint genomics has played in other high-profile murder cases. DNAPrint's forensics technology has been used in nearly 100 law enforcement investigations since its introduction.
posted
DNAPrint genomics to Effect 1-for-20 Stock Consolidation on Tuesday, July 12 PR Newswire - July 6, 2005 7:00 AM (EDT)
-------------------------------------------------------------------------------- Jump to first matched term
SARASOTA, Fla., July 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today announced that its Board of Directors has authorized a 1-for-20 consolidation of the Company's stock, effective at 12:01 a.m. Eastern time on Tuesday, July 12, 2005.
Shareholders at the Company's annual meeting on June 23 approved an amendment to the Company's Articles of Incorporation authorizing a stock combination of at least 1-for-10 but no more than 1-for-20 with the exact ratio established by the Board of Directors.
Following the stock consolidation, DNAPrint genomics will have approximately 62,000,000 shares outstanding.
"The stock consolidation will enable DNAPrint genomics to access up to $40 million in capital from equity line draws for future growth and potential acquisitions," stated President and Chief Executive Officer Richard Gabriel. "The central focus of our strategic plan is to build up our pharmaceutical division by placing new drugs into the pipeline. At the same time, we plan to expand our forensics division based on the growing success of our product line for law enforcement."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. ( http://www.dnaprint.com ) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT- 401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre- clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response.
IP: Logged |
posted
Updated: 07:34 AM EDT DNAPrint genomics Ancestry and Forensics Technologies Featured in TIME Magazine and Toronto Globe and Mail Articles
SARASOTA, Fla., July 7 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today announced that the rising popularity in determining family heritage and the utilization of forensic technology for law enforcement have generated articles about the Company in two major media publications.
An article in this week's edition of TIME magazine noted that more than 100,000 Americans, including celebrities such as Oprah Winfrey and Spike Lee, have taken genealogical DNA tests offered by commercial laboratories to learn more about their family history.
TIME told the story of Brent Kennedy of Wise, Va., who thought that he was of English and Scotch-Irish descent, even though he felt that members of his family looked more Arabic than English. After taking DNAPrint's EUROWITNESS 1.0(TM) test, Mr. Wise learned that he was 45% Northern and Western European, 25% Middle Eastern, 25% Turkish-Green and 5% South Asian.
posted
DNAPrint genomics Ticker Symbol Changing to 'DNAG'
SARASOTA, Fla., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today announced that commencing with the opening of the market on Tuesday, July 12, 2005, the Company's Common Stock will begin trading on the Over-the-Counter Bulletin Board under the symbol "DNAG."
The change of the symbol is the result of a stock consolidation approved by shareholders and the Board of Directors that also becomes effective the same day.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
